Savara/$SVRA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Savara
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.
Ticker
$SVRA
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
59
Website
Savara Metrics
BasicAdvanced
$544M
-
-$0.49
0.44
-
Price and volume
Market cap
$544M
Beta
0.44
52-week high
$4.74
52-week low
$1.89
Average daily volume
1.2M
Financial strength
Current ratio
14.914
Quick ratio
14.653
Long term debt to equity
19.999
Total debt to equity
20.08
Profitability
EBITDA (TTM)
-108.244
Management effectiveness
Return on assets (TTM)
-38.97%
Return on equity (TTM)
-75.77%
Valuation
Price to book
3.67
Price to tangible book (TTM)
3.96
Price to free cash flow (TTM)
-5.572
Free cash flow yield (TTM)
-17.95%
Free cash flow per share (TTM)
-46.30%
Growth
Earnings per share change (TTM)
32.41%
3-year earnings per share growth (CAGR)
22.53%
What the Analysts think about Savara
Analyst ratings (Buy, Hold, Sell) for Savara stock.
Bulls say / Bears say
Savara has completed the submission of a Biologics License Application (BLA) to the FDA for MOLBREEVI as a treatment for autoimmune pulmonary alveolar proteinosis (aPAP), indicating potential for future revenue upon approval. (Business Wire)
The company has secured non-dilutive debt financing of up to $200 million with Hercules Capital, providing substantial capital to support ongoing operations and development without diluting shareholder value. (Business Wire)
Savara's stock has shown a 12% increase over the past year, outperforming the S&P 500's 26.09% gain, reflecting positive investor sentiment. (Yahoo Finance)
Savara's return on equity (ROE) has decreased to -0.39 as of December 31, 2023, from -0.36 the previous year, indicating declining profitability. (Sirius Investors)
The company's current ratio has declined to 15.66 on December 31, 2023, from 21.98 the previous year, suggesting a decrease in short-term liquidity. (Sirius Investors)
Savara's stock price is 86.71% below its 52-week high of $5.34, indicating significant volatility and potential investor concerns. (Marketing Sentinel)
Data summarised monthly by Lightyear AI. Last updated on 12 Jul 2025.
Savara Financial Performance
Revenues and expenses
Savara Earnings Performance
Company profitability
Savara News
AllArticlesVideos
Savara Announces New Employment Inducement Grant
Business Wire·1 week ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRA
Accesswire·1 month ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRA
Accesswire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Savara stock?
Savara (SVRA) has a market cap of $544M as of July 28, 2025.
What is the P/E ratio for Savara stock?
The price to earnings (P/E) ratio for Savara (SVRA) stock is 0 as of July 28, 2025.
Does Savara stock pay dividends?
No, Savara (SVRA) stock does not pay dividends to its shareholders as of July 28, 2025.
When is the next Savara dividend payment date?
Savara (SVRA) stock does not pay dividends to its shareholders.
What is the beta indicator for Savara?
Savara (SVRA) has a beta rating of 0.44. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.